Stem cell genomics

Researchers Assemble Nine Synthetic Yeast Chromosomes

Retrieved on: 
Wednesday, November 8, 2023
3D, Survival, Evolution, Small RNA, Water, Vaccine, Biochemistry, Human, Saccharomyces cerevisiae, CRISPR, Genetics, Claisen rearrangement, Livestock, NYU Langone Health, Stem cell genomics, Publication, Doctor of Philosophy, Q-system (genetics), Virus, Research, Protein, Multimedia, Nature, Environment, Sol, Rest, Growth, Genome, Luo, Down syndrome, Medicine, McCulloch, Meiosis, Soil, Bacteria, Gene, Scramble, Synthetic biology, Gene expression, Chromosome, Cell division, DNA, Molecular Cell, Cell

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- A team led by researchers at NYU Langone Health has built nine new synthetic yeast chromosomes, swapping out a key organism's genetic material for engineered replacements.

Key Points: 
  • NEW YORK, Nov. 8, 2023 /PRNewswire/ -- A team led by researchers at NYU Langone Health has built nine new synthetic yeast chromosomes, swapping out a key organism's genetic material for engineered replacements.
  • In 2014, Sc2.0 reported the building of the first synthetic yeast chromosome (synthetic chromosome 3, or synIII), and five additional chromosomes (synII, synV, synVI, synX, and synXII) followed by 2017.
  • The team's challenge now, after having assembled all 16 synthetic yeast chromosomes, is to consolidate them into a single living yeast strain, the authors said.
  • Dr. Zhao and colleagues just published in Cell their significant progress on this front by incorporating 6.5 synthetic yeast chromosomes into one yeast cell using an established, but tedious method.

Vizgen Installs 100th MERSCOPE® Instrument

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Health, Genetics, Stem Cells, Oncology, Retina, IPSC, Alpha, Baylor College of Medicine, Deep learning, Baylor University, Nature Communications, Multimedia, Research, Cell, BioRxiv, Preprint, Genome Biology, Transcriptome, B cell, Machine learning, Stem cell genomics, Neuroscience, Mouse, Vaccine, Microscope, Core

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it has installed its 100th MERSCOPE instrument in the Single Cell Genomics Core at the Baylor College of Medicine Department of Molecular and Human Genetics led by Dr. Rui Chen.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it has installed its 100th MERSCOPE instrument in the Single Cell Genomics Core at the Baylor College of Medicine Department of Molecular and Human Genetics led by Dr. Rui Chen.
  • View the full release here: https://www.businesswire.com/news/home/20230725541683/en/
    Terry Lo, President and CEO of Vizgen with Rui Chen, Ph.D., Professor of Molecular and Human Genetics and Director of the Center of Single Cell Omics at the Baylor College of Medicine.
  • (Photo: Business Wire)
    Genetics plays an important role in human visual disorders which affect more than 30 million people in the United States alone1.
  • “It is extremely gratifying that Dr. Chen will be the recipient of the 100th installation of our MERSCOPE Platform as a longstanding supporter of Vizgen and the power of spatial imaging,” said Terry Lo, President and CEO of Vizgen.

Replay receives $1.5 million grant for its hypoimmunogenic technology platform

Retrieved on: 
Monday, November 28, 2022
Sir, Skin, KKR, IPS, University, DNA, Brain, Regenerative medicine, Bill, Patient, Potency (pharmacology), IPSC, Protein engineering, Induce, Genome, HSV, Pathology, Neurodegeneration, Infection, Cancer, Paul Ruddock, Writing, Stem cell genomics, Synthetic biology, Sir William Dunn School of Pathology, Bill & Melinda Gates Foundation, AAV, Biology, Eye, Pharmaceutical industry, Vaccine, Replay

Replays uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.

Key Points: 
  • Replays uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.
  • The technology is relevant to both the developed and developing worlds, with the anticipated reduced cost-of-goods improving equity of access.
  • Lachlan MacKinnon, Chief Executive Officer, and Co-Founder of Replay, added: Replays hypoimmunogenic technology is the result of a convergence of synthetic biology, computational design, and protein engineering with iPS cell technology.
  • The Companys hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms.

Global Single Cell Genomics Markets Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 22, 2022
Health, Genetics, Single cell, Immunology, B cell, Microbiology, Research, Biotechnology, Technology, Genomics, Stem cell genomics, Single cell sequencing, Sales

Single Cell Genomics is emerging as a mainstay of scientific research and development.

Key Points: 
  • Single Cell Genomics is emerging as a mainstay of scientific research and development.
  • But the largest market is still in research and the market is booming as understanding the genomics of individual cells opens up a whole new world of biotechnology.
  • Get a firm handle on understanding the enormous potential of Single Cell Genomics with this comprehensive report.
  • This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

Global Induced Pluripotent Stem Cells Markets 2021-2026: Molecular and Cellular Engineering, Cellular Reprogramming, Cell Culture, Cell Differentiation, and Cell Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, Stem cells, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Stem cell genomics

The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • For this report, iPSC products do not cover stem cell research and clinical products, which are broadly applicable to any stem cell type.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSCs market.

Induced Pluripotent Stem Cells: Global Markets

Retrieved on: 
Monday, January 27, 2020
Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Cell biology, Developmental biology, IPSCS, Induced pluripotent stem cell, IPSC, Stem cell genomics

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology.The market has gradually become an important part of the life sciences industry during recent years.

Key Points: 
  • It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology.The market has gradually become an important part of the life sciences industry during recent years.
  • - The U.S. government has been encouraging the marketing of stem cells, including iPSCs.
  • - Rapidly growing medical tourism and contract research outsourcing drives the Asia-Pacific stem cell market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Stem Cell Therapy Contract Manufacturing Market, 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 3, 2019
Health, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cell therapy, Stem-cell therapy, Induced stem cells, Stem cell genomics

The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies.

Key Points: 
  • The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies.
  • Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies.
  • As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs).
  • A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology).

Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research

Retrieved on: 
Wednesday, July 11, 2018
Biology, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Stem cell, Adult stem cell, Embryonic stem cell, Stem cell controversy, Stem cell genomics

From a product perspective, the global stem cell market can be divided into adult stem cells and embryonic stem cells.

Key Points: 
  • From a product perspective, the global stem cell market can be divided into adult stem cells and embryonic stem cells.
  • From a geography perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress.
  • The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market."
  • We are continuing to expand the cell culture facilities to include therapeutic cell research, development, and production in the cGMP suites."